GlassScriptPhysician profile
Olivia Cochran
NPI 1184176786
$3,903.05
in general payments reported to CMS, 2019-2025
30 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,493 · 2022: $1,141 · 2023: $786 · 2024: $274 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $613.78 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $532.20 | 2021-2024 | |
| Glaxosmithkline, LLC. | $391.36 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.47 | 2021-2023 | Jardiance, Tradjenta |
| Lilly USA, LLC | $272.16 | 2021-2023 | Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $177.15 | 2021-2024 | Farxiga |
| Amgen INC. | $158.11 | 2021-2023 | Repatha |
| Pfizer INC. | $121.31 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.38 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.11 | 2021-2023 | Caplyta |
| Sanofi-Aventis U.S. LLC | $108.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $108.80 | 2021-2023 | Spravato |
| Merck Sharp & Dohme LLC | $103.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $102.52 | 2022-2025 | |
| Dexcom, INC. | $86.75 | 2021-2023 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $86.23 | 2021-2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $83.84 | 2025 | Cobenfy |
| Insulet Corporation | $65.87 | 2021 | |
| Nestle Healthcare Nutrition INC. | $58.27 | 2022 | |
| Corcept Therapeutics | $50.96 | 2023 | Korlym |
| Corium, LLC | $44.47 | 2022-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $30.73 | 2022 | |
| Astellas Pharma US INC | $30.47 | 2021-2022 | |
| Axsome Therapeutics, INC. | $29.20 | 2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $28.78 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.99 | 2022 | |
| Allergan, INC. | $17.91 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.67 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.